Optometry - ModernMedicine

Optometry

Editor's Choice
Besifloxacin ophthalmic suspension 0.6% is approved for bacterial conjunctivitis
Besifloxacin ophthalmic suspension 0.6% (Besivance, Bausch & Lomb) was approved recently by the FDA for the treatment of bacterial conjunctivitis. Besifloxacin suspension is able to fight bacteria that are growing resistant to older anti-infectives.
LATEST ARTICLES
BRAVO Study: Ranibizumab shows benefit in BRVO
Data analyses collected in a phase III clinical trial show a strong benefit of intravitreal ranibizumab for clearing macular edema and rehabilitating vision in patients who have suffered a branch retinal vein occlusion.
PHP device aids CNV detection
A new device for at-home monitoring of age-related macular degeneration is a promising tool for early detection of choroidal neovascularization.
Benefits of lutein: MERG study shows improved VA
Results of a second phase study showed patients with category 3 dry age-related macular degeneration (AMD) can achieve increased and sustained visual acuity levels with administration of correct carotenoids, vitamins and minerals.
Metabolic mapping: Application images RPE
Blue laser autofluorescence has important clinical applications in the study of geographic atrophy and other retinal diseases.
Vasculopathies: Data support intravitreal bevacizumab
Data continue to support intravitreal bevacizumab injection for treatment of radiation maculopathy and radiation optic neuropathy.
eSamples check closet
eSamples check closet
Practice ToolsPractice Tools
Coding Counselor
Coding Counselor

Simple and accurate ICD-9 code search. Start Here

Patient Education
Patient Education

Print customized patient education handouts. Start Here

Surgical Video Center
Surgical Video Center

On-demand surgery demos and presentations. Start Here



Click here